Smoking
Conditions
Keywords
adoption, electronic cigarettes, e-cigarettes, combustible cigarettes, nicotine polacrilex, own brand cigarette, subjective measures, pharmacokinetics, pharmacodynamics
Brief summary
The purpose of this study is to measure plasma nicotine uptake parameters, physiological measures, and subjective effect measures in smokers during and following a single ad libitum use of three electronic cigarettes versus combustible cigarettes and nicotine gum.
Detailed description
This study will assess various elements that may provide information regarding the potential for electronic cigarettes (e-cigarettes) to be adopted by current smokers. These various elements include: a) nicotine pharmacokinetics (PK), b) physiological measures of pulse rate and blood pressure, and c) subjective effects measured by Urge to Smoke, Product Rating, Intent to Use Product Again, and Product Effects.
Interventions
OTHEROwn Brand Cigarette
combustible cigarette brand style smoked most frequently by subject
VUSE® Digital Vapor Cigarette (original flavor, 14mg nicotine)
VUSE® Digital Vapor Cigarette (original flavor, 29mg nicotine)
VUSE® Digital Vapor Cigarette (original flavor, 36mg nicotine)
4 mg nicotine polacrilex gum
Sponsors
Celerion
RAI Services Company
R.J. Reynolds Vapor Company
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. Able to read, understand, and willing to sign an informed consent form and complete questionnaires written in English. 2. Generally healthy male or female, 21 to 60 years of age, inclusive, at Screening. 3. Expired breath carbon monoxide (ECO) level is ≥ 15 ppm and ≤ 100 ppm at the Screening and Randomization Visits, measured between 12 p.m. and 6 p.m. 4. Cigarettes are the only tobacco product used within (≤) 30 days of Screening. 5. Smokes combustible, filtered, non-menthol cigarettes, 83 mm to 100 mm in length. 6. Agrees to smoke usual brand (UB) cigarette throughout the study period. Usual brand cigarette is defined as the cigarette brand style currently smoked most frequently by the subject. 7. Smokes at least 10 cigarettes per day (on average) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of the Investigator. 8. Response at Screening to Fagerstrom Test for Nicotine Dependence, Question 1 (How soon after you wake up do you smoke your first cigarette?) is either Within 5 minutes or 6 - 30 minutes. 9. Willing to use UB cigarette, the study electronic cigarette brand styles and nicotine gum during the study period. 10. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to check-in at each Test Visit. 11. Willing to not participate for 60 days post-study in donation of blood samples or in any study that requires collection of blood samples. 12. Females of childbearing potential must be willing to use a form of contraception acceptable to the Investigator from the time of signing informed consent until study discharge.
Exclusion criteria
1. Clinically significant or unstable/uncontrolled acute or chronic medical conditions at Screening, as determined by the Investigator, that would preclude a subject from participating safely in the study (e.g., uncontrolled hypertension, asthma or other lung disease, cardiac disease, neurological disease or psychiatric disorders) based on safety assessments such as clinical laboratory tests, medical history, and physical/oral examinations. 2. Systolic blood pressure of \> 150 mmHg or a diastolic blood pressure of \> 95 mmHg at Screening, measured after being seated for at least 5 minutes. 3. Hemoglobin level is \< 12 g/dL at Screening. 4. Positive test for Human Immunodeficiency Virus (HIV), Hepatitis B surface antigen, or Hepatitis C virus. 5. Postponing a decision to quit smoking (defined as planning a quit attempt within \[≤\] 30 days of Screening) to participate in this study or previous attempt within (≤) 30 days prior to Screening. 6. Employed by a tobacco company, the study site, or handles unprocessed tobacco as part of their job. 7. Use of any medication or supplement that aids smoking cessation, including but not limited to any nicotine replacement therapy (e.g., nicotine gum, lozenge, patch), varenicline (Chantix), bupropion (Wellbutrin, Zyban), or lobelia extract within (≤) 30 days of Screening. 8. Females ≥ 35 years of age currently using systemic, estrogen containing contraception or hormone replacement therapy. 9. A positive urine drug screen without disclosure of corresponding prescribed concomitant medication(s), at Screening or Randomization Visit. A positive alcohol result at Screening, Randomization Visit, or at any Test Visit. 10. A female who is pregnant, lactating, or intends to become pregnant during the course of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Baseline cotinine measured pre-IP use | -0.5 minute only for each IP, over 5 weeks | Evaluate changes in baseline cotinine to assess whether subjects substantially changed their nicotine exposure during the study |
| Maximum change in pulse rate relative to baseline | Baseline and at timed intervals over 360 minutes following initiation of IP use | Determine the maximum change in pulse rate |
| Change in expired carbon monoxide (ECO) relative to baseline | Baseline and 35 minutes post-IP use | Assess change in ECO from baseline following IP use |
| Nicotine pharmacokinetics with respect to initiation of in-clinic investigational product (IP) use following a 12-hour tobacco and nicotine abstinence | -5, -0.5, 3, 5, 7.5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240, 300, 360 minutes | Determine area under the plasma nicotine concentration versus time curve (AUC) |
| Nicotine pharmacokinetics with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence | -5, -0.5, 3, 5, 7.5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240, 300, 360 minutes | Determine maximum plasma nicotine concentration (Cmax), baseline adjusted |
| Subjective effects scores for Urge to Smoke (UTS) with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence | -10, 5, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360 minutes | Score subjective effects using a numeric rating scale (NRS) to determine area under the UTS score-versus-time curve \[area under the effect curve (AUEC)\], minimum UTS score, and time to minimum UTS score |
| Subjective effects scores for Intent to Use Again (IUA) with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence | 15, 30, 45, 60, 120, 180, 240, 300, 360 minutes | Score subjective effects using a NRS to determine area under the IUA score-versus-time curve (AUEC) and maximum IUA score |
| Subjective effects scores for Product Ratings (PR) with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence | 15, 30, 45, 60, 120, 180, 240, 300, 360 minutes | Score subjective effects using a NRS to determine area under the PR score-versus-time curve (AUEC) and maximum PR score |
| Subjective effects scores for positive Product Effects (PE) with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence | 15, 30, 45, 60, 120, 180, 240, 300, 360 minutes | Score subjective effects using a NRS to determine area under the positive PE score-versus-time curve (AUEC) and maximum positive PE score |
| Subjective effects scores for negative Product Effects (PE) with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence | 15, 30, 45, 60, 120, 180, 240, 300, 360 minutes | Score subjective effects using a NRS to determine area under the negative PE score-versus-time curve (AUEC) and maximum negative PE score |
Other
| Measure | Time frame | Description |
|---|---|---|
| Perform both CYP2A6 genotyping and phenotyping (i.e., nicotine metabolic ratio of cotinine:3-OH cotinine) | Time of randomization | A) Determine the impact of CYP2A6 genotype and phenotype on nicotine uptake and subjective effects following a 12-hour tobacco and nicotine abstinence and B) Explore a potential relationship between CYP2A6 genotype and phenotype |
| Maximum change in blood pressure relative to baseline | Baseline and at timed intervals over 360 minutes following initiation of IP use | Determine the maximum change in blood pressure |
Countries
United States
Outcome results
None listed